Tuesday, June 2, 2026

Suboxone Filings Surge as Talc and Depo-Provera Dockets Expand

We tracked 115 new filings yesterday. Volume was heavily driven by concentrated plaintiff activity across established pharmaceutical and medical device dockets. The Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation (MDL 3092) led the day with 23 new complaints, all brought by Ask Law. The Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation (MDL 3140) drew 12 cases from a coalition of firms including MCH Law PLLC, Aylstock Witkin Kreis Overholtz PLLC, and Heninger Garrison Davis.

New Mexico Attorney General Sues E-Betting Platform Kalshi Over Illegal Gambling

On June 5, 2026, the New Mexico attorney general announced a lawsuit against the e-betting platform Kalshi, alleging the company operates an illegal online gambling business. The enforcement action claims that the prediction markets, which allow users to wager on real-world events, violate state gaming laws and consumer protection statutes by aggressively targeting local residents without proper regulatory oversight. The lawsuit seeks immediate injunctive relief to halt operations in the state, alongside significant civil penalties for deceptive trade practices. For plaintiffs' attorneys monitoring the emerging sports betting addiction litigation space, this aggressive state-level intervention highlights the escalating regulatory scrutiny and expanding liability risks facing digital wagering platforms that operate outside traditional gaming frameworks.

CeraVe Faces Class Actions Over Benzene Contamination Claims

On June 4, 2026, multiple class action lawsuits were reported against L'Oréal's CeraVe brand over allegations that its popular acne products contain dangerously high levels of benzene, a known human carcinogen. The complaints assert that the skincare staple's formulation and packaging lead to the degradation of active ingredients, resulting in toxic benzene exposure for consumers who use the over-the-counter treatments. Plaintiffs are advancing failure-to-warn and design defect claims, arguing the company concealed the contamination risk despite growing industry awareness of benzene formation in aerosolized and chemical-based dermatological products. For product liability practitioners, this litigation represents a significant expansion of the ongoing benzene exposure dockets, shifting focus from aerosol antiperspirants and sunscreens directly onto foundational, daily-use skincare brands.